In 2024, Beroni Group and the School of Software, Tsinghua University officially reached a cooperation agreement to jointly develop the AI-based R&D Model. This cooperation marks the deep integration of both AI and pharmaceutical R&D, injecting new impetus into the innovative development of the pharmaceutical industry. This project is progressing smoothly and has achieved technological breakthroughs.
This model can utilize big data and machine learning techniques to provide more accurate and personalized solutions for disease diagnosis and treatment. After research, the model has strong feasibility and possesses the following five capabilities: First, it can design candidate antibodies that meet clinical level therapeutic antibody standards, and even screen candidate antibody libraries; Second, it can design targeted binding protein inhibitors with high water solubility and stability; Third, it can be design efficient enzyme protein variants with better substrate binding and catalytic abilities; Fourth, it can design T cell receptors with better tumor antigen recognition ability; Fifth, it can design small molecule targeted compounds with good protein target specific binding ability.
Beroni Group, as a company dedicated to pharmaceutical research and innovation, has been actively exploring AI applications in the field of pharmaceutical R&D. The advances in this AI-based drug R&D model further enhances the Group’s strength in the fields of AI and pharmaceutical R&D, promotes the Group’s innovative development in new drug R&D, disease diagnosis and treatment, and contributes more to the innovative development of the pharmaceutical industry. This technology can also be leverage to support the development of other core projects of the Group.
